Isomorphic Labs raises $5 billion in a Series C — the largest AI drug discovery raise on record — as the London DeepMind spinout moves toward its first clinical trials.
THE ROUND
Isomorphic Labs closes $5B Series C for AI-designed drugs
Announced 17 November, Isomorphic Labs — the AI drug-discovery company spun from Google DeepMind and led by Nobel laureate Demis Hassabis — raised $5 billion in a Series C, the largest raise in AI-based drug discovery on record.
Greenoaks and Sequoia Capital co-led; Andreessen Horowitz joined as a new investor. Existing backers include GV, CapitalG, Thrive Capital, MGX, Temasek, and the UK Sovereign AI Fund. Bloomberg had earlier reported funding talks at a $50 billion implied valuation.
The raise follows a $2.1 billion Series B in May 2026. The company has struck deals with Eli Lilly, Novartis, and Johnson & Johnson, and has reported positive preclinical results in oncology and immunology. Hassabis expects the company's first clinical trials by end of 2026.
FOR FOUNDERS
What the raise signals for European AI-for-science
The capital stack shows how European science can scale to global frontier rounds. Isomorphic's core engine builds on AlphaFold, the protein-structure model that earned Hassabis and John Jumper the Nobel Prize in Chemistry in 2024.
The UK Sovereign AI Fund's direct participation — alongside Temasek and three of the world's largest VC funds — sets a new benchmark for state-backed AI investment. The model: spin a research asset from a world-class lab, build to preclinical proof, then raise at frontier scale.
For founders in AI-for-science, computational biology, and drug discovery: the European institutional stack can now support and attract US-tier capital. The question is no longer whether this category scales. It is how fast.
The weekly briefing
Funding calls, VC news and key deadlines. Free to read; unsubscribe anytime.